Our top pick for
MediWound Ltd is a biotechnology business based in the US. MediWound shares (MDWD) are listed on the NASDAQ and all prices are listed in US Dollars. MediWound employs 74 staff and has a trailing 12-month revenue of around USD$20.5 million.
|52-week range||USD$1.4427 - USD$6.07|
|50-day moving average||USD$5.0945|
|200-day moving average||USD$3.994|
|Wall St. target price||USD$6.9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.243|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing MediWound stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MediWound's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MediWound's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, MediWound shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
MediWound's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8.2 million.
The EBITDA is a measure of a MediWound's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$20.5 million|
|Gross profit TTM||USD$19.9 million|
|Return on assets TTM||-13.23%|
|Return on equity TTM||-82.22%|
|Market capitalisation||USD$138.7 million|
TTM: trailing 12 months
There are currently 37,045 MediWound shares held short by investors – that's known as MediWound's "short interest". This figure is 66.3% up from 22,278 last month.
There are a few different ways that this level of interest in shorting MediWound shares can be evaluated.
MediWound's "short interest ratio" (SIR) is the quantity of MediWound shares currently shorted divided by the average quantity of MediWound shares traded daily (recently around 205805.55555556). MediWound's SIR currently stands at 0.18. In other words for every 100,000 MediWound shares traded daily on the market, roughly 180 shares are currently held short.
However MediWound's short interest can also be evaluated against the total number of MediWound shares, or, against the total number of tradable MediWound shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MediWound's short interest could be expressed as 0% of the outstanding shares (for every 100,000 MediWound shares in existence, roughly 0 shares are currently held short) or 0.0028% of the tradable shares (for every 100,000 tradable MediWound shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MediWound.
Find out more about how you can short MediWound stock.
We're not expecting MediWound to pay a dividend over the next 12 months.
Over the last 12 months, MediWound's shares have ranged in value from as little as $1.4427 up to $6.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MediWound's is 1.5315. This would suggest that MediWound's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.